On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy

Yi Wen Huang, Shoichi Takahashi, Masataka Tsuge, Chi Ling Chen, Ting Chuan Wang, Hiromi Abe, Jui Ting Hu, Ding Shinn Chen, Sien Sing Yang, Kazuaki Chayama, Jia Horng Kao

Research output: Contribution to journalArticlepeer-review

47 Citations (Scopus)

Abstract

Background: Serum HBV RNA is detectable during nucleoside/nucleotide analogue therapy as a result of unaffected RNA replicative intermediates or interrupted reverse transcription. We studied the predictive value of serum HBV RNA for initial virological response during nucleoside analogue therapy. Methods: Serum HBV RNA was quantified before and at 12 and 24 weeks of lamivudine or entecavir therapy. Serum HBV DNA was measured every 4-12 weeks during treatment to define initial virological response. Results: Serum HBV RNA was detectable in 21 of 52 (40%) consecutive patients with a mean of 5.2 log copies/ml (male/female 35/17, mean age of 60 years with a range of 31-82, 44% HBeAg-positive, and 26 with lamivudine and 26 with entecavir) before treatment. Serum HBV RNA level at week 12 in patients with an interval from detectable to undetectable serum HBV DNA level <16 weeks was significantly lower than those with an interval ≥16 weeks (3.8 ±3.8 versus 6.6 ±3.5 log copies/ml, P=0.013). After adjustment for serum HBV DNA level at week 12, serum quantatitive HBsAg level at week 12 and pretreatment ALT level, low serum HBV RNA level at week 12 predicted a shorter interval to undetectable serum HBV DNA level (adjusted hazard ratio =0.908, 95% CI 0.829, 0.993, P=0.035). Conclusions: Low serum HBV RNA level at week 12 of nucleoside analogue therapy independently predicts initial virological response in treated chronic hepatitis B patients. Serum HBV RNA levels may thus be useful for optimizing treatment of chronic hepatitis B.

Original languageEnglish
Pages (from-to)369-375
Number of pages7
JournalAntiviral Therapy
Volume20
Issue number4
DOIs
Publication statusPublished - 2015

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy'. Together they form a unique fingerprint.

Cite this